- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00005113
A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant
An Open-Label, Comparative Study of the Effect of Sirolimus Versus Standard Treatment on Clinical Outcomes and Histologic Progression of Allograft Nephropathy in High Risk Pediatric Renal Transplant Patients
The purpose of this study is to compare treatment with the new drug sirolimus (SRL) versus the standard treatment with cyclosporine (CsA) or tacrolimus in children who have received kidney transplants. SRL is a new medication that may prevent the body's immune system from rejecting organ transplants.
After receiving a kidney transplant, the body recognizes the donated kidney as a foreign invader and triggers the immune system to attack the kidney. This can lead to rejection of the new kidney and a failed transplant. To help reduce the risk of kidney rejection, transplant patients are given immunosuppressant drugs, which reduce the body's normal immune response and allow the transplanted organ to function. CsA or tacrolimus are two drugs that are often given to transplant patients. However, these are powerful drugs, and it can cause serious side effects and put a patient at increased risk for infections. SRL is a new drug that has been shown to reduce a transplant patient's chance of rejecting a new kidney, without serious side effects. This study is necessary to test the safety and effectiveness of SRL in children.
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
Successful kidney transplantation has gradually improved over the years; much of the improvement has resulted from the use of CsA. However, adequate and tolerable immunosuppression is difficult to achieve with CsA, and rejection episodes are still frequent. CsA is nephrotoxic, with drug toxicity often masking rejection episodes. Other immunosuppressant therapies can result in a range of complications, including metabolic disturbances, adrenocortical insufficiency, and increased risk for infections. Therefore, more effective drugs with less toxicity are needed to prevent acute rejection, especially in the pediatric population where the overall graft survival rate remains significantly lower when compared with that of adult transplant recipients. SRL is an immunosuppressive agent being developed for the prophylaxis of acute renal allograft rejection. SRL has a unique mechanism of action. It inhibits T and B cell activity. In Phase I and II trials in adults, SRL was generally well tolerated and exhibited no apparent nephrotoxic properties, and significantly lower rates of rejection were seen with SRL when compared to placebo.
Patients receive extensive prestudy screening, which includes a renal core biopsy, chest x-ray, bone density study, blood tests, and glomerular filtration rate (GFR). Patients are then randomly assigned to 1 of 2 study treatment groups in a 2:1 ratio (142 patients receive SRL, CsA/tacrolimus, and corticosteroids and 71 patients receive standard CsA or tacrolimus-based double or triple drug therapy). SRL is administered as an oral dose of 3 mg/m2/day. Patients are followed for 3 years on therapy, and then for 1 month of follow-up. A renal core biopsy is performed at the time of study entry and at Months 6, 18, and at early termination of patient in study. Patients undergo physical examinations and various blood tests at specified time intervals during the 37-month study period. Efficacy is assessed by comparing the composite endpoint of biopsy-proven acute rejection, graft loss, or death after 36 months of treatment. Safety is assessed by comparing the composite endpoint of graft loss or death after 36 months of treatment.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Children's Hospital Boston
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria
Your child may be eligible for this study if he/she:
- Has received a kidney transplant.
- Has experienced 1 or more episodes of acute rejection or chronic rejection; a rejection episode must have responded to treatment and have occurred at least 30 days before study enrollment.
- Has stable kidney function at the time of study enrollment.
- Is 20 years of age or younger.
- Has written informed consent of parent or guardian if under the age of 18.
- Agrees to use birth control during the study and for 3 months following treatment.
Exclusion Criteria
Your child will not be eligible for this study if he/she:
- Has a history of cancer.
- Has received a multi-organ transplant (more than a kidney).
- Has an active infection.
- Has an abnormal chest X-ray.
- Cannot provide a kidney biopsy at time of study entry.
- Is allergic to sirolimus.
- Has received experimental drugs within 4 weeks of study entry.
- Is pregnant.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: 1
Participants will receive SRL, CsA/tacrolimus, and corticosteroids for up to 36 months
|
Oral tablet taken daily.
Dosage is dependent on weight and is titrated to target trough level.
Otros nombres:
Dosage in liquid or tablet form is dependent on body surface area and is titrated to target trough level.
Otros nombres:
dosage is in oral form titrated to target trough level
|
Experimental: 2
Participants will receive standard CsA or tacrolimus-based double or triple drug therapy for up to 36 months
|
Oral tablet taken daily.
Dosage is dependent on weight and is titrated to target trough level.
Otros nombres:
dosage is in oral form titrated to target trough level
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Safety and efficacy of sirolimus
Periodo de tiempo: Throughout study
|
Throughout study
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Composite endpoint of biopsy proven acute rejection, graft loss, or death
Periodo de tiempo: At Months 6, 12, and 24
|
At Months 6, 12, and 24
|
Rate of clinically diagnosed acute rejection
Periodo de tiempo: At months 6, 12, 24, and 36
|
At months 6, 12, 24, and 36
|
Rate of change in glomerular filtration rate
Periodo de tiempo: At Month 18
|
At Month 18
|
Mean change in volume of allograft fibrosis
Periodo de tiempo: At Months 6 and 18
|
At Months 6 and 18
|
Intragraft expression of cytokines
Periodo de tiempo: Throughout study
|
Throughout study
|
Cytokine expression and subsequent development of chronic allograft nephropathy
Periodo de tiempo: Throughout study
|
Throughout study
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades Renales
- Enfermedades urológicas
- Insuficiencia renal
- Insuficiencia Renal Crónica
- Insuficiencia Renal Crónica
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Agentes antiinfecciosos
- Inhibidores de enzimas
- Agentes antirreumáticos
- Agentes antineoplásicos
- Agentes inmunosupresores
- Factores inmunológicos
- Agentes dermatológicos
- Agentes antibacterianos
- Antibióticos, Antineoplásicos
- Agentes antifúngicos
- Inhibidores de calcineurina
- Tacrolimus
- Sirolimus
- Ciclosporina
- Ciclosporinas
Otros números de identificación del estudio
- DAIT SRL1
- DAIT 0468E1-217-US
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .